Opaleye Management Inc.
CIK 1595855 · View on SEC EDGAR ↗
- Portfolio value
- $1.1B
- Positions
- 58
- As of
- June 30, 2026
#2,288 of 9,443 by 13F value · top 24.2%
Portfolio value QoQ: +45.4% 13F does not disclose cash
- Top 10 holdings weight
- 64.76%
- Top 25 holdings weight
- 88.49%
- Positions above 1%
- 27
- Effective number of positions
- 15.3
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 10.42% Est. buys $156,683,181 · sells $97,118,328
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 52.3% still held
- New positions
- 13
- Increased
- 15
- Decreased
- 13
- Closed
- 8
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +62.6% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 96.6% · Options excluded: 0.0%
Sector breakdown
Healthcare
99.7%
Other/Unmapped
0.3%
Full portfolio 58 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| LQDA Liquidia Corporation - Common Stock | $195,139,175 | 17.67% | 2,447,500 | $106,318,675 | Down ×1 | ||
| ETON Eton Pharmaceuticals, Inc. - Common Stock | $103,532,000 | 9.38% | 2,860,000 | $32,947,200 | |||
| HROW Harrow, Inc. - Common Stock | $101,928,000 | 9.23% | 2,400,000 | $2,063,570 | Down ×2 | ||
| IRON Disc Medicine, Inc. - Common Stock | $62,534,700 | 5.66% | 855,000 | $35,615,960 | Up ×5 | ||
| URGN UroGen Pharma Ltd. - Ordinary Shares | $52,991,853 | 4.80% | 1,439,996 | $27,280,453 | Up ×2 | ||
| APGE Apogee Therapeutics, Inc. - Common Stock | $51,764,700 | 4.69% | 390,000 | $18,938,400 | |||
| MGTX MeiraGTx Holdings plc - Ordinary Shares | $47,960,500 | 4.34% | 3,550,000 | $29,573,077 | Up ×2 | ||
| SLGL Sol-Gel Technologies Ltd. - Ordinary Shares | $37,070,000 | 3.36% | 500,000 | $-2,540,000 | |||
| RZLT Rezolute, Inc. - Common Stock (NV) | $32,760,000 | 2.97% | 6,300,000 | $13,545,000 | |||
| TGTX TG Therapeutics, Inc. - Common Stock | $29,392,900 | 2.66% | 535,000 | $11,620,200 | |||
| IMMX Immix Biopharma, Inc. - Common Stock | $24,176,950 | 2.19% | 2,345,000 | Up ×1 | |||
| CBIO Crescent Biopharma, Inc. - Common Stock | $23,748,318 | 2.15% | 1,319,351 | $-364,420 | Up ×2 | ||
| STOK Stoke Therapeutics, Inc. - Common Stock | $22,904,000 | 2.07% | 700,000 | $112,000 | |||
| ACOG Alpha Cognition Inc. - Common Stock | $20,905,272 | 1.89% | 2,895,467 | $6,840,166 | Up ×3 | ||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $20,315,000 | 1.84% | 500,000 | $4,565,000 | |||
| RVMD Revolution Medicines, Inc. - Common Stock | $18,728,000 | 1.70% | 100,000 | $9,003,000 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $18,029,000 | 1.63% | 745,000 | Up ×1 | |||
| ALMS Alumis Inc. - Common Stock | $15,477,000 | 1.40% | 550,000 | $3,360,500 | |||
| CDXS Codexis, Inc. - Common Stock | $15,334,100 | 1.39% | 6,785,000 | $4,274,550 | |||
| REPL Replimune Group, Inc. - Common Stock | $15,331,873 | 1.39% | 1,384,993 | Up ×1 | |||
| XOMA XOMA Royalty Corporation - Common Stock | $14,380,895 | 1.30% | 338,374 | $4,969,895 | Up ×3 | ||
| MBX MBX Biosciences, Inc. - Common Stock | $14,352,000 | 1.30% | 260,000 | $6,591,000 | |||
| RYTM Rhythm Pharmaceuticals, Inc. - Common Stock | $13,601,175 | 1.23% | 122,500 | $-21,722,025 | Down ×6 | ||
| EDIT Editas Medicine, Inc. - Common Stock | $12,512,653 | 1.13% | 3,861,930 | $7,752,970 | Up ×1 | ||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $12,258,000 | 1.11% | 100,000 | $1,718,000 | |||
| CABA Cabaletta Bio, Inc. - Common Stock | $12,016,418 | 1.09% | 3,863,800 | $8,304,218 | Up ×3 | ||
| QTTB Q32 Bio Inc. - Common Stock | $11,860,940 | 1.07% | 931,000 | $3,795,956 | Down ×1 | ||
| ANNX Annexon, Inc. - common stock | $9,789,515 | 0.89% | 1,714,451 | $-3,128,441 | Down ×2 | ||
| VSTM Verastem, Inc. - Common Stock | $6,876,000 | 0.62% | 1,800,000 | Up ×1 | |||
| ZNTL Zentalis Pharmaceuticals, Inc. - common stock | $6,851,382 | 0.62% | 1,412,656 | $3,545,767 | |||
| RLMD Relmada Therapeutics, Inc. - Common Stock | $6,470,200 | 0.59% | 935,000 | $-37,400 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $5,892,000 | 0.53% | 600,000 | $810,000 | |||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $5,781,500 | 0.52% | 310,000 | $1,664,457 | Down ×1 | ||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $5,334,000 | 0.48% | 700,000 | $4,857,126 | Up ×1 | ||
| LYEL Lyell Immunopharma, Inc. - Common Stock | $4,833,551 | 0.44% | 344,025 | $3,246,865 | Up ×1 | ||
| IRD Opus Genetics, Inc. - Common Stock | $4,623,750 | 0.42% | 1,125,000 | $2,372,550 | Up ×1 | ||
| FDMT 4D Molecular Therapeutics, Inc. - Common Stock | $4,448,012 | 0.40% | 334,437 | $3,402,583 | Up ×1 | ||
| NTLA Intellia Therapeutics, Inc. - Common Stock | $4,230,000 | 0.38% | 250,000 | $1,089,100 | Up ×1 | ||
| VYGR Voyager Therapeutics, Inc. - Common Stock | $4,147,500 | 0.38% | 1,185,000 | $-291,500 | Up ×1 | ||
| BDSX Biodesix, Inc. - Common Stock | $4,059,000 | 0.37% | 180,000 | $607,318 | Down ×1 | ||
| RCKT Rocket Pharmaceuticals, Inc. - Common Stock | $3,420,000 | 0.31% | 1,000,000 | $1,100 | Up ×1 | ||
| JBIO Jade Biosciences, Inc. - Common Stock | $3,221,900 | 0.29% | 145,000 | $-2,785,992 | Down ×1 | ||
| SNWV SANUWAVE Health, Inc. - Common Stock | $3,061,400 | 0.28% | 306,140 | $-13,904,706 | Down ×1 | ||
| FBIO Fortress Biotech, Inc. - Common Stock | $2,723,400 | 0.25% | 890,000 | $-183,780 | Down ×2 | ||
| DERM Journey Medical Corporation - Common Stock | $2,478,000 | 0.22% | 350,000 | $-2,024,400 | Down ×2 | ||
| PHAT Phathom Pharmaceuticals, Inc. - Common Stock | $2,013,641 | 0.18% | 185,589 | Up ×1 | |||
| INBX Inhibrx Biosciences, Inc. - Common Stock | $1,922,572 | 0.17% | 20,291 | Up ×1 | |||
| ENTA Enanta Pharmaceuticals, Inc. - Common Stock | $1,822,500 | 0.17% | 125,000 | $243,750 | |||
| Unknown issuer (CUSIP: 423494103) | $1,750,258 | 0.16% | 47,652 | Up ×1 | |||
| Unknown issuer (CUSIP: 337185102) | $1,307,800 | 0.12% | 65,000 | Up ×1 | |||
| CGON CG Oncology, Inc. - Common stock | $1,263,908 | 0.11% | 17,789 | $-5,152,156 | Down ×2 | ||
| BHVN Biohaven Ltd. Common Shares | $1,159,375 | 0.10% | 77,915 | Up ×1 | |||
| AVIR Atea Pharmaceuticals, Inc. - common stock | $1,092,750 | 0.10% | 235,000 | $-642,838 | Down ×1 | ||
| KTTA Pasithea Therapeutics Corp. - Common Stock | $1,056,570 | 0.10% | 2,050,000 | Up ×1 | |||
| ADCT ADC Therapeutics SA Common Shares | $749,000 | 0.07% | 700,000 | ||||
| OKYO OKYO Pharma Limited - Ordinary Shares | $562,806 | 0.05% | 375,204 | Up ×1 | |||
| PTN Palatin Technologies, Inc. - Common Stock | $221,195 | 0.02% | 20,500 | Up ×1 | |||
| ADGM Adagio Medical Holdings, Inc - Common Stock | $13,353 | 0.00% | 18,444 | $-7,858 | |||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| IMMX | $24,176,950 | 2,345,000 | 2.19% |
| GLUE | $18,029,000 | 745,000 | 1.63% |
| REPL | $15,331,873 | 1,384,993 | 1.39% |
| VSTM | $6,876,000 | 1,800,000 | 0.62% |
| PHAT | $2,013,641 | 185,589 | 0.18% |
| INBX | $1,922,572 | 20,291 | 0.17% |
| Unknown issuer (CUSIP: 423494103) | $1,750,258 | 47,652 | 0.16% |
| Unknown issuer (CUSIP: 337185102) | $1,307,800 | 65,000 | 0.12% |
| BHVN | $1,159,375 | 77,915 | 0.10% |
| KTTA | $1,056,570 | 2,050,000 | 0.10% |
| ADCT | $749,000 | 700,000 | 0.07% |
| OKYO | $562,806 | 375,204 | 0.05% |
| PTN | $221,195 | 20,500 | 0.02% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| LQDA | Trimmed | -98K | +$106.3M |
| IRON | Bought more | +434K | +$35.6M |
| ETON | Price move only | +0 | +$32.9M |
| MGTX | Bought more | +1.4M | +$29.6M |
| URGN | Bought more | +10K | +$27.3M |
| RYTM | Trimmed | -500 | -$21.7M |
| APGE | Price move only | +0 | +$18.9M |
| RZLT | Price move only | +0 | +$13.5M |
| TGTX | Price move only | +0 | +$11.6M |
| RVMD | Price move only | +0 | +$9.0M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| IMNM | Dec. 31, 2025 | 3,185,000 | $37,296,350 | 33.1% |
| CATX | June 30, 2026 | 4,675,000 | $19,494,750 | No longer tracked |
| ALKS | March 31, 2026 | 490,000 | $13,710,200 | 39.5% |
| SRPT | Dec. 31, 2025 | 585,000 | $11,272,950 | -11.0% |
| LRMR | Dec. 31, 2025 | 3,720,867 | $10,564,900 | 8.0% |
| JSPR | March 31, 2025 | 400,000 | $8,552,000 | -82.6% |
| GOSS | March 31, 2026 | 2,720,000 | $8,432,000 | -52.8% |
| ARVN | Dec. 31, 2025 | 987,818 | $8,416,209 | -20.2% |
| NAMS | March 31, 2025 | 325,000 | $8,352,500 | 36.6% |
| VIGL | Sept. 30, 2025 | 1,000,000 | $7,950,000 | No longer tracked |
| KPTI | March 31, 2026 | 930,000 | $6,844,800 | -65.5% |
| ANIK | Sept. 30, 2025 | 588,797 | $6,229,472 | 126.2% |
| PCVX | March 31, 2025 | 75,000 | $6,139,500 | 63.1% |
| DNA | Sept. 30, 2025 | 500,000 | $5,625,000 | -48.0% |
| ASRT | June 30, 2026 | 265,707 | $5,064,375 | No longer tracked |
| PVLA | June 30, 2025 | 172,357 | $4,824,272 | 539.9% |
| STRO | June 30, 2026 | 190,671 | $4,749,615 | -36.3% |
| TMCI | Dec. 31, 2025 | 702,245 | $4,712,064 | 79.2% |
| ANAB | June 30, 2025 | 250,933 | $4,664,844 | 161.7% |
| NUVL | March 31, 2025 | 58,500 | $4,579,380 | No longer tracked |
| SLRN | June 30, 2025 | 1,615,000 | $3,989,050 | No longer tracked |
| TECX | June 30, 2026 | 123,000 | $3,801,930 | 5.2% |
| EPIX | Sept. 30, 2025 | 2,209,998 | $3,756,997 | No longer tracked |
| ZYME | March 31, 2026 | 108,929 | $2,868,101 | 6.5% |
| ABCL | March 31, 2025 | 965,000 | $2,827,450 | 426.5% |
| CRGX | Sept. 30, 2025 | 666,503 | $2,745,992 | No longer tracked |
| ADCT | Dec. 31, 2025 | 682,529 | $2,730,116 | -70.6% |
| TARA | Sept. 30, 2025 | 855,000 | $2,590,650 | -10.1% |
| URGN | March 31, 2025 | 220,000 | $2,343,000 | 343.9% |
| VTYX | March 31, 2026 | 251,932 | $2,274,946 | No longer tracked |
| RCEL | Sept. 30, 2025 | 389,519 | $2,060,556 | 99.6% |
| BDSXXXXX | June 30, 2025 | 3,225,000 | $2,016,270 | No longer tracked |
| RIGL | June 30, 2026 | 70,000 | $1,892,800 | 15.8% |
| OPTN | June 30, 2025 | 193,039 | $1,770,168 | No longer tracked |
| GBIO | March 31, 2026 | 310,000 | $1,760,800 | No longer tracked |
| NXTC | June 30, 2026 | 141,181 | $1,507,813 | 306.3% |
| BBIO | March 31, 2026 | 18,319 | $1,401,220 | 12.1% |
| KNSA | June 30, 2025 | 62,501 | $1,388,147 | 187.9% |
| NRIX | June 30, 2025 | 115,000 | $1,366,200 | 136.8% |
| IMTX | March 31, 2025 | 165,000 | $1,173,150 | 94.7% |
| SYRE | Dec. 31, 2025 | 65,000 | $1,089,400 | 223.4% |
| LXEO | March 31, 2025 | 130,000 | $855,400 | 50.1% |
| PLX | June 30, 2026 | 340,000 | $737,800 | No longer tracked |
| SGMO | June 30, 2025 | 1,055,000 | $691,869 | No longer tracked |
| RGNX | March 31, 2025 | 80,000 | $618,400 | 59.5% |
| ELEV | Sept. 30, 2025 | 1,442,061 | $529,381 | No longer tracked |
| SLN | March 31, 2026 | 78,926 | $479,870 | 150.7% |
| LBRX | June 30, 2026 | 14,506 | $357,718 | 48.8% |
| PEPG | Dec. 31, 2025 | 75,000 | $346,500 | -52.1% |
| IBIO | Dec. 31, 2025 | 375,000 | $310,425 | -24.9% |
| VTYX | June 30, 2025 | 190,000 | $218,500 | No longer tracked |
| RAPT | March 31, 2026 | 150,000 | $213,363 | No longer tracked |